Replies to post #170094 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

In recent years Dr. Gabrilovich is focused on the role of lipid accumulation in the defective function of DCs and MDSC in cancer.

LIPIDS=PS?

Thanks bio.

wook

[Hypi]

How is Wall Street not connecting these dots and running with this stock? Looks like July options are very active, so maybe the Greece event is the coming out party?

[spankyvol]

So why doesn't KOL Dmitry Gabrilovich just say... PS Targeting?

[biopharm]

Gabrilovich together with investigators from other institutions coined the term “myeloid-derived suppressor cells (MDSC)” which is now widely used to characterize these cells. Since 2007, when the term was introduced by Gabrilovich and colleagues, more than 600 papers studying these cells were published.

On one post I made the statement that it was Dmitry that coined the term MDSC "Myeloid-derived suppressor cells", so correcting that here in which it was Dmitry Gabrilovich "with investigators" that coined that term MDSC's. So here are, little old Peregrine Pharmaceuticals out in Tustin, CA bringing on board 4 global KOL's all at once back on Dec 10, 2013.... which is pretty historic in itself for a small biotech to attract the attention of, so where is this all leading?

1) Dec 10... the 4 key KOL's were added:... for now just looking at the Bavi- MOA on PS targeting that is being slowly peeled back like an onion by Dmitry Gabrilovich, which will make any Big Pharma exec cry in hopes of having the PS targeting platform.

Scott Antonia
Dmitry Gabrilovich
Hakan Mellstedt
David Carbone

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94846768

2) Now Dmitry is the MD and talking expert on MDSC's:
.... and how they are "DIRECTLY" related to immune suppression. We are on the ice bergs edge of a gigantic amount of data ready to roll in on why MDSC's suppress the immune system and these are the reasons why we have Dmitry Gabrilovich by Peregrines side. He (Dmitry) has spent a lifetime studying MDSC and the trouble it causes the immune system and in comes Dr. Rolf Brekken with a nice synopsis of PS targeting and how it effects MDSC's... thats all Dmitry needed to hear!

Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98093801&txt2find=MDSC%27%27s

3) Under Subpart H, approval may be based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity ...

there are a few key links in this reference post below, and we now the FDA has the capability of approving Bavi+Docetexal during that 1st interim look, "IF" a surrogate endpoint or an effect on a clinical endpoint... is met. Primary endpoint is overall survival and since we know patients have been known to live much longer while taking Bavi... it needs to be scientifically proven! Hence... the reason for the KOL's again "AND" possibly the reason why they are involved in other conference (Notsch Signaling.... etc..etc and they begin to provide a great amount of background data on what exactly is changing and why it benefits patients if it does... example: MDSC's

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95747264&txt2find=MDSC%27%27s

4) Now you may hear some talking about not getting excited over pre-clinical data, well you need pre-clinical data, especially specific data re: ligands, receptors... etc dealing directly with PS targeting and the chain reaction that occurs thereafter, to make it easier for the FDA to undertsand on that first interim look-in

Just as many researchers are trying to figure out what combinations to try and they just figure try them all! and then see the patient population that does well and try to move that certain inhibitor drug towards that patient class for a "VERY SMALL" footprint of patients that it may help -VS- the universal biomarker of all biomarkers in stressed/cancer cells that helps all patient groups and ALL-subgroups in Bavituximab and PS targeting. PS exists in all humans, plants, animals... but no time for that in this post. So for now.... just showing below how the lack of pre-clinical is widespread and we need those preclinicals, along with KOL's detailing whats happens when MDSC's are affected... (many of these conferences do not say PS Targeting or Bavituximab or Peregrine!... but very easy to connect those dots when at the very end of these presentations they simply have to say: "Oh, PS targeting can be achieved by a drug such as Bavituximab.... " Dmitry looks to be working on "connecting the dots" for the medical community from the other side of the spectrum and digging deeper into the "chain reaction" part of why the role of MDSC's are vital to even having a chance at providing the "optimal immune response"

Cambridge Healthtech Institute’s 2nd Annual
Immunomodulatory Therapeutic Antibodies for Cancer
Discovery and Development of the Next Wave of Checkpoint Inhibitors
August 11-12, 2014

Myeloid-Derived Suppressor Cells – Emerging Regulators of Immune Responses

But the path forward for this important direction in cancer treatment is not an easy one for researchers. The lack of relevant preclinical models, biomarkers and established clinical endpoints creates a challenge in demonstrating efficacy and advancing therapeutics through development. And the management of immune-related adverse events has become an important consideration in the development and clinical application of this class of biotherapeutics.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97585093&txt2find=MDSC

5) Again, Dmitry lands this time in Greece on June 25-27 - Mykonos, Greece --- ... when I first made this reference post below, I failed to see this lines importance and Myeloid Cell Differentiation is "DIRECTLY" part of Notch Targeting but what causes this "chain reaction" ??? That is the question! Again, they do not say PS targeting or Bavituximab or mention Peregrine.... but how easy is it to connect those dots after reading up on the MOA of Bavituximab and the changes it mades upon MDSC's ?? Rather simple I say now...and for all these reasons, you now know why Dmitry Gabrilovich landed at Peregrine after working a lifetime on studying MDSC's and how Bavituximab and PS targeting changes the overall approach in combinational therapy, immune therapy... and simply how there is no way in hell you can say cancer immunotherapy without first having PS targeting involved.

Effects of Notch Signaling on Regulation of Myeloid Cell
Differentiation in Cancer

investorshub.advfn.com/boards/read_msg.aspx?message_id=95547560&txt2find=dmitry|greece

6) I could go on and on and I forget more than half of the details in a post like this that I should include but that will be for another day.... so I say the problem begins with flipped-PS, but I probably just say that because I have written it soo many times now after seeing "Hyeryun Choe" say just that and he happens to be speaking today... April 1st, 2014 on this subject specifically!

"This is where the trouble begins"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99804759&txt2find=choe

-----------------------------------------------------

So the next time you look at another day of no news of PS targeting... think again. The word is spreading on all the presentations/events above that will not be on Peregrines newsfeed or PR'd, but they are slowly going to cause havoc in Big Pharma Land and soo much havoc that some may even try to say look at the BOD, look at the stock price, look at how many years its been lol

I'd like to mention that Billions of dollars have been spent globally and and how many cancer organizations do we have ? Hundreds of them that some have been in business for 100+ years and guess who discovered flipped-PS and Bavituximab?

Dr. Philip Thorpe

... may he rest in peace, but I wouldn't be surprised if he'd like to kick some Big Pharma A$$ and hopefully Peregrine fulfills that part.

http://www.utsouthwestern.edu/newsroom/center-times/year-2013/may/obit-thorpe.html

[biopharm]

The more I keep looking over this Conference on Notch Targeting in Cancer and Peregrine KOL Dmitry Gabrilovich presenting, the more I see this will directly reinforce the MOA of Bavituximab and show the astronomical value that PS targeting presents in cancer and vaccines.

Notch signalling: a simple pathway
becomes complex

Sarah J. Bray

Abstract |

A small number of signalling pathways are used iteratively to regulate cell fates, cell proliferation and cell death in development. Notch is the receptor in one such pathway, and is unusual in that most of its ligands are also trans membrane proteins; therefore signalling is restricted to neighboring cells. Although the intracellular transduction of the Notch signal is remarkably simple, with no secondary messengers, this
pathway functions in an enormous diversity of developmental processes and its dysfunction is implicated in many cancers.

http://mcdb.colorado.edu/labs1/xue/MCDB4426/pdf%20files/Notch%20review%202.pdf

This is one part of Notch Signaling I've read in a few publications but posting this one-- in that the signaling is between adjacent or neighboring cells which makes sense. A tumor grows and can metastasize to another non-adjacent organ/part of the body.

This publication is from 2006 and does not mention Phosphatidylserine or flipped-PS.... because it was not understood at the time and I can guarantee that Dr. Dmitry Gabrilovich, at the Notch Signaling (but notice how its called Notch Targeting?) ... will make big mention of Phosphatidylserine.

I think that is another big part of calling it "Notch Targeting" .... target flipped-PS (which is part of Notch) and magic happens.

Time will tell....

[volgoat]

One reason why is whether myeloid derived suppresor cells truly play a role in human disease is a long ways from being proven.